Short answer
Benitec Biopharma Inc. (BNTC) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$9M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$9M
- −77.2% YoY
- EPS (diluted)
- −$0.22
- +54.2% YoY
Source: XBRL data from the Benitec Biopharma Inc. (BNTC) Q3 2025 10-Q on SEC EDGAR. USD.
Benitec Biopharma Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue and YoY change not disclosed in provided MD&A
- Profitability margins and percentage changes not disclosed in provided MD&A
- BB-301 strongest development performance: Cohort 1, 100% response rate across six patients
- All six subjects safely treated; no treatment-related severe adverse events observed
- Additional financing required to advance BB-301 development and clinical programs
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and signatures
- November 5, 2025 securities purchase agreement and underwriting agreement indicate new financing activity
- Registration Rights Agreement dated November 7, 2025 creates potential future share-registration obligations
- No disclosed defaults upon senior securities or Rule 10b5-1 trading arrangements for quarter ended September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Benitec Biopharma Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.